购注销 2023 年限制性股票激励计划部分限制性股票 1,324,260 股，公司总股本 由 1,828,780,926 股减至 1,827,456,666 股，因本次利润分配的股本基数以扣除 公司回购注销的股权激励限售股份数量 1,324,260 股后的 1,827,456,666 股为基 数，本次分配比例不变,公司按照分配比例不变的原则对分配总额进行调整，总 计分配 365,491,333.20 元。 是一致的。 二、权益分派方案 本公司2024年年度权益分派方案为：以公司现有总股本1,827,456,666股为 基数，向全体股东每10股派2.00元人民币现金（含税；扣税后，通过深股通持有 股份的香港市场投资者、境外机构（含QFII、RQFII）以及持有首发前限售股的 个人和证券投资基金每10股派1.80元；持有首发后限售股、股权激励限售股及无 限售流通股的个人股息红利税实行差别化税率征收，本公司暂不扣缴个人所得税， 待个人转让股票时，根据其持股期限计算应纳税【注】；持有首发后限售股、股 权激励限售股及无限售流通股的证券投资基金所涉红利税，对香港投资者持有基 金份额部分按10%征收，对内地投资者持有基金份 ...

Core Viewpoint - The research conducted by Wuhan University focuses on the mechanism by which PCSK9 promotes the degradation of LDLR, offering new hope for the treatment of hypercholesterolemia [2][3]. Group 1: Research Findings - The study reveals that PCSK9 obstructs the recycling of LDLR, leading to its degradation in lysosomes, which is critical for understanding cholesterol metabolism [2]. - Various cell lines, including HuH7 and LDLR knockout HuH7 cells, were utilized to explore the intricate regulatory mechanisms between PCSK9 and LDLR [2]. - The research involved multiple experimental stages, including validating the impact of SNX17 on LDLR recycling and investigating how PCSK9 interferes with this process [2]. Group 2: Product Usage - The research utilized ExCell Bio FSP500, a premium fetal bovine serum, which is essential for maintaining cell growth and functionality in vitro [3]. - The choice of fetal bovine serum is crucial, as improper selection can significantly affect experimental outcomes and publication potential [6]. Group 3: Industry Standards and Safety - The International Serum Industry Association (ISIA) emphasizes the importance of traceability in serum sourcing to ensure product quality and safety [6]. - The prevalence of smuggled serum from countries with frequent bovine diseases poses significant safety risks for researchers [8]. - Recent incidents, such as the smuggling case involving 12 million yuan worth of bovine serum, highlight the need for stringent regulations and compliance in the serum industry [10]. Group 4: Company Credentials - ExCell Bio is recognized as a leading global manufacturer of fetal bovine serum, with a strong commitment to safeguarding biological safety [12][14]. - The company ensures that all serum products are traceable to their source and meet rigorous quality standards through proper documentation [14][15].

Domestic Financial Market - In May, the national consumer price index (CPI) decreased by 0.1% year-on-year, while the producer price index (PPI) fell by 3.3% year-on-year [4] - In May, China's total goods trade import and export value reached 3.81 trillion yuan, an increase of 2.7%, with exports growing by 6.3% and imports declining by 2.1% [4] Industry Dynamics - The upcoming Volcano Engine Power Conference is expected to benefit the AI industry chain, with related stocks including Hand Information (300170) and Runxin Technology (300493) [5] - During the "618" shopping festival, beauty products became the main sales force on e-commerce platforms, with related stocks such as Marubi Biotechnology (603983) and Proya Cosmetics (603605) [5] - The satellite internet industry is accelerating its progress, with institutions indicating potential for valuation expansion, related stocks include Shanghai Huguang (603131) and Parker New Materials (605123) [5] Company Focus - Longshen Rongfa (300534) received CNAS laboratory accreditation for its controlling subsidiary, which is expected to positively impact future operations [6] - Fangsheng Pharmaceutical (603998) obtained a drug registration certificate for its innovative traditional Chinese medicine product [6] - Fuda Alloy (603045) saw its controlling shareholder increase holdings by 7,700 shares [6] - Maixinlin (688685) signed a 1.184 billion yuan computing power service contract, which is expected to positively affect the company's performance in 2025 and beyond [6] Market Review and Outlook - On June 9, the market opened slightly higher and continued to rise, with the Shanghai Composite Index closing at 3,399 points, up 0.43%, and the ChiNext Index rising over 1% [7] - The market showed broad gains with over 4,200 stocks rising, while sectors like chemical pharmaceuticals, aerospace equipment, and cultural media performed well [7] - The market is expected to break out of its current range if incremental capital continues to flow in, with a focus on holding positions and seeking low-level opportunities [8]

Core Viewpoint - The company has approved the use of idle fundraising for cash management, allowing investment in safe, liquid principal-protected products up to a maximum of RMB 1.5 billion [2][11]. Group 1: Cash Management Overview - The company plans to use idle funds from its non-public stock issuance to invest in principal-protected financial products, enhancing the efficiency and returns of the raised funds while ensuring no impact on ongoing projects [4][9]. - The cash management will involve a maximum of RMB 800 million in a structured deposit product from Hangzhou Bank, with a term of 364 days [6][10]. Group 2: Financial Product Redemption - The company redeemed a structured deposit product from Hangzhou Bank worth RMB 50 million, receiving the principal and a return of RMB 585,900 on June 6, 2025 [3]. Group 3: Financial Situation and Impact - As of March 31, 2025, the company's cash reserves were RMB 1,874.59 million, with the cash management investment representing 4.27% of total cash, indicating minimal impact on financial health [11]. - The use of idle funds for cash management is expected to improve fund utilization efficiency and generate returns for shareholders without affecting the company's operational projects [11].

热景生物6月9日龙虎榜 6月9日热景生物（688068）收盘价161.15元，收盘上涨18.15%，全天换手率6.41%，振幅24.46%，成交 额9.02亿元。科创板交易公开信息显示，当日该股因日收盘价涨幅达15%等上榜。 证券时报·数据宝统计显示，上榜的前五大买卖营业部合计成交3.79亿元， 其中，买入成交额为2.37亿 元，卖出成交额为1.42亿元，合计净买入9503.95万元。具体来看，今日上榜的前五大买入营业部中，有 3家机构专用席位现身，即买一、买四、买五，买入金额分别为8867.62万元、3117.17万元、2460.83万 元，营业部合计买入9260.57万元。卖出营业部中，有1家机构专用席位现身，即卖二，卖出金额分别为 3442.21万元，营业部合计卖出1.08亿元。买卖金额相抵，机构专用席位今日净买入该股1.10亿元。 资金流向方面，该股今日全天主力资金净流入5174.91万元。（数据宝） | 买入营业部名称 | 买入金额(万元) | | --- | --- | | 机构专用 | 8867.62 | | 国盛证券有限责任公司深圳粤海街道证券营业部 | 4746.58 | | 高盛(中国)证 ...

证券代码：300239 证券简称：东宝生物 公告编号：2025-049 债券代码：123214 债券简称：东宝转债 包头东宝生物技术股份有限公司 关于 2024 年度权益分派实施后调整 回购股份价格上限和数量的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 包头东宝生物技术股份有限公司(以下简称"公司")于 2025 年 1 月 3 日召 开第九届董事会第八次会议、第九届监事会第七次会议，审议通过了《关于回购 公司股份方案的议案》。根据相关法律法规及《公司章程》规定，本次回购股份 方案无需提交公司股东大会审议。使用公司自有资金和/或自筹资金以集中竞价 交易方式或法律法规允许的方式回购部分公司已发行的人民币普通股(A 股)股票， 并在未来适宜时机将回购股份用于实施员工持股计划或股权激励。本次回购价格 不超过人民币 8.00 元/股(含)，本次回购股份的实施期限为公司董事会审议通过 回购股份方案之日起 12 个月内。按照回购股份价格上限人民币 8.00 元/股，回 购金额下限人民币 5,000 万元-上限人民币 10,000 万元(含)测算，预计回购股份 数 ...

关注创新药行情全面扩散下的投资机会 证 券 研 究 报 告 2025下半年医药生物行业投资策略 证券分析师：张静含 A0230522080004 2025.6.9 投资案件 一改颓势，医药板块上半年表现亮眼 -15% -10% -5% 0% 5% 10% 15% 20% 25% 2025/01/02 化学制药 生物制品 医疗器械 医药商业 中药 医疗服务 年初至今医药及大盘涨跌幅对比 年初至今医药二级板块涨跌幅对比 -10% -8% -6% -4% -2% 0% 2% 4% 6% 8% 10% 25/01 25/02 25/03 25/04 25/05 25/06 相对全A涨跌幅 医药生物(申万) 万得全A(除金融、石油石化) www.swsresearch.com 证券研究报告 2 ◼ 年初至6/5，医药生物（申万）指数年初至今累计涨跌幅为+8.0%，同期万得全A（除金融石油石化）涨跌幅为 +2.7%，相对大盘涨跌幅为+5.2%，在申万一级行业中排名第5。从二级行业行情表现来看，年初至今涨跌幅排名分 别为：化学制药（35.0x→41.6x）、生物制品（29.8x→41.6x）、医疗器械（30.3x→34.7 ...

Group 1 - Kaichun Co., Ltd. adjusted the share repurchase price limit from 26.625 yuan/share to 40 yuan/share, effective from June 10, 2025 [1] - Yipin Pharmaceutical's subsidiary received a drug registration certificate for Dexmedetomidine Hydrochloride Injection, a Class 3 chemical drug used for sedation during anesthesia [1] - Bohui Innovation obtained a medical device registration certificate for HPV Genotyping Test Kit, used for qualitative detection of HPV DNA [1][2] Group 2 - Lingyi Zhi Zao's application for issuing convertible bonds and cash payment to acquire 66.46% of Jiangsu Kedasiteng Automotive Technology Co., Ltd. has been accepted by the Shenzhen Stock Exchange [3] - Kemin Food reported a 23.06% year-on-year increase in pig sales in May, with a total of 48,300 pigs sold [4][5] - Meian Sen decided to terminate the issuance of shares to specific objects due to market conditions and strategic considerations [6][7] Group 3 - Zhengbang Technology reported a 146.6% year-on-year increase in pig sales revenue in May, totaling 731 million yuan [9] - Yuanda Holdings plans to reduce the registered capital of its subsidiary from 73 million to 24.3 million USD to optimize asset structure [10] - East China Pharmaceutical's subsidiary received FDA approval for clinical trials of HDM1010 tablets for type 2 diabetes [12] Group 4 - Liangxin Co., Ltd. received a government subsidy of 14.1 million yuan, accounting for 4.52% of its audited net profit for 2024 [13] - Erkang Pharmaceutical's Vitamin B6 Injection passed the consistency evaluation for generic drugs [14] - New Industry received a patent certificate for an antibody related to anti-PIC detection, enhancing detection efficiency [16][15] Group 5 - Dongxing Medical signed a 6 million yuan technology development contract with Shanghai Jiao Tong University for collagen preparation processes [16] - Suchang Chai A's subsidiary will absorb and merge another subsidiary, adjusting internal equity structure [17] - Yibin Technology received a project designation notice from a domestic new energy vehicle company, with an estimated total sales of 256 million yuan over five years [18] Group 6 - Mingchen Health received a cash dividend of 20 million yuan from its subsidiary [19] - Hendi Pharmaceutical obtained a drug registration certificate for Ibuprofen Suspension, a common medication for children [19] - Huaren Pharmaceutical's subsidiary received a drug registration certificate for Dexmedetomidine Hydrochloride Injection, classified as a Category B drug under national medical insurance [20] Group 7 - Enwei Pharmaceutical obtained a renewed drug production license for six key products [21] - Xiaoming Co., Ltd. reported a 45.59% year-on-year increase in chicken product sales in May, totaling 23.25 million birds [23][24] - Shan Natural Gas successfully issued a 350 million yuan short-term financing bond with a 1.78% interest rate [25] Group 8 - Xidamen announced plans for board members to reduce their holdings by up to 581,000 shares [26] - Shentong Technology's shareholder plans to reduce holdings by up to 3% of the company's shares [27] - Saintno Bio plans to distribute a cash dividend of 0.14 yuan per share and a capital increase of 0.4 shares per share [28] Group 9 - *ST King Kong's subsidiary received a debt transfer notice from its controlling shareholder, totaling 364 million yuan [29] - Foxit Software's executives plan to reduce their holdings by a total of 55,800 shares [30] - Youyou Green Energy plans to apply for a bank credit line of up to 1.5 billion yuan [31] Group 10 - Guoxing Optoelectronics plans to distribute a cash dividend of 0.5 yuan per 10 shares [32] - Guangxun Technology plans to distribute a cash dividend of 2.6 yuan per 10 shares [33] - Hanrui Cobalt plans to distribute a cash dividend of 1.5 yuan per 10 shares [35] Group 11 - Tigermed plans to distribute a cash dividend of 3 yuan per 10 shares [37] - Shenliang Holdings plans to distribute a cash dividend of 1.5 yuan per 10 shares [38] - Yishitong plans to distribute a cash dividend of 1 yuan per 10 shares [39]

Market Overview - On June 9, the A-share market saw all three major indices close higher, with the Shanghai Composite Index rising by 0.43% to 3399.77 points, the Shenzhen Component Index increasing by 0.65% to 10250.14 points, and the ChiNext Index up by 1.07% to 2061.29 points. The total trading volume in the Shanghai and Shenzhen markets reached 128.64 billion yuan, an increase of 13.44 billion yuan compared to the previous trading day [1]. Industry Performance - The pharmaceutical sector exhibited the strongest performance on June 9, with chemical pharmaceuticals reaching a nearly four-year high, immunotherapy hitting a two-year high, and weight-loss drugs achieving a one-and-a-half-year high. Other segments such as generic drugs and hepatitis treatments also reached new highs for the year [2]. - In May, at least six domestic innovative pharmaceutical companies announced business development (BD) transactions, primarily involving cross-border cooperation with foreign pharmaceutical companies. Additionally, at the recent ASCO conference, 73 research projects from China were selected for oral presentations, including 11 significant research abstracts [2]. Company Insights - Lingpai Technology, a notable stock on June 9, saw its share price increase by over 10%. The company specializes in the research, production, and sales of new environmentally friendly surface engineering chemicals. In Q1 2025, Lingpai reported an earnings per share of -0.15 yuan and a net profit attributable to shareholders of -26.63 million yuan, with a year-on-year growth rate of 14.54%. The company has completed the research and development of the NCM811 battery chemical system and is actively involved in the new energy vehicle, energy storage, and engineering machinery sectors [4].

Investment Rating - The investment rating for the company is "Buy" [7] Core Viewpoints - The report is optimistic about the commercialization prospects of the company's products, including the monoclonal antibody "Sai Li Qi" and the bispecific antibodies GR2002 and GR1803, anticipating data readouts that could enhance valuation [1] - The company achieved significant revenue growth in 2024, with total revenue reaching 30.10 million yuan, and a slight narrowing of net losses to 797 million yuan [1] - The company has a differentiated pipeline with key products progressing steadily, including the approval of Sai Li Qi for moderate to severe plaque psoriasis and ankylosing spondylitis [1][2] Financial Performance - In Q1 2025, the company reported revenue of 20.16 million yuan and a net loss of 121 million yuan, with R&D expenses at 10.30 million yuan [1] - Revenue projections for 2025-2027 are estimated at 199 million yuan, 533 million yuan, and 1.07 billion yuan respectively, reflecting a strong growth trajectory [4][6] - The company maintains high R&D expenditure, with 610 million yuan in 2024, indicating a commitment to innovation [1] Pipeline Development - The GR1802 monoclonal antibody is progressing through clinical trials for multiple indications, with significant market potential [2] - The GR1801 rabies virus antibody is currently under review for market approval, with promising commercial prospects [2] - Other pipeline products, including GR2001 and GR1803, are advancing through clinical stages and partnerships, demonstrating the company's innovative capabilities [3]